During the past decade, Kepler Universitätsklinikum Med Campus III. conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 3 clinical trials were completed, i.e. on average, 25% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 3 clinical trials were completed. i.e. 37.5% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Kepler Universitätsklinikum Med Campus III." #1 sponsor was "Medtronic Cardiac Rhythm and Heart Failure" with 5 trials, followed by "Bayer" with 4 trials sponsored, "Alliance Foundation Trials, LLC." with 1 trials sponsored, "Universität des Saarlandes" with 1 trials sponsored and "Vivostat" with 1 trials sponsored. Other sponsors include -5 different institutions and companies that sponsored additional 5 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Kepler Universitätsklinikum Med Campus III." #1 collaborator was "AF Schimetta GMbH" with 1 trials as a collaborator, "Austrian Breast & Colorectal Cancer Study Group" with 1 trials as a collaborator, "Breast International Group" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator and "European Commission" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "Kepler Universitätsklinikum Med Campus III." are "Atrioventricular Conduction Block" (2 trials), "Acute Myocardial Infarction" (1 trials), "Acute Respiratory Distress Syndrome" (1 trials), "Anastomotic Leak Rectum" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Kepler Universitätsklinikum Med Campus III." in a lesser frequency.

Most popular intervention types in "Kepler Universitätsklinikum Med Campus III." are "Device" (6 trials), "Drug" (6 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)" (1 trials), "Aflibercept VEGF Trap-Eye (Eylea, BAY86-5321)" (1 trials), "Arctic Front™ Cardiac Cryoablation Catheter System" (1 trials), "BAY1097761 Active Dose 1" (1 trials) and "BAY1097761 Active Dose 2" (1 trials). Other intervention names were less common.

The vast majority of trials in "Kepler Universitätsklinikum Med Campus III." are 11 trials for "All" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "Kepler Universitätsklinikum Med Campus III.". undefined are not yet recruiting, 6 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 3 completed trials in Kepler Universitätsklinikum Med Campus III., undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Kepler Universitätsklinikum Med Campus III., 1 "Phase 1" clinical trials were conducted, 3 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 3 trials that are defined as “Not Applicable".